Production of bile by the liver is crucial for the absorption of lipophilic nutrients. Dysregulation of bile acid homeostasis can lead to cholestatic liver disease and endoplasmic reticulum (ER) stress. We show by global location analysis ('ChIP-on-chip') and cell type-specific gene ablation that the winged helix transcription factor Foxa2 is required for normal bile acid homeostasis. As suggested by the location analysis, deletion of Foxa2 in hepatocytes in mice using the Cre-lox system leads to decreased transcription of genes encoding bile acid transporters on both the basolateral and canalicular membranes, resulting in intrahepatic cholestasis. Foxa2-deficient mice are strikingly sensitive to a diet containing cholic acid, which results in toxic accumulation of hepatic bile salts, ER stress and liver injury. In addition, we show that expression of FOXA2 is markedly decreased in liver samples from individuals with different cholestatic syndromes, suggesting that reduced FOXA2 abundance could exacerbate the injury.
The liver has a major role in the detoxification of xenobiotics, metabolism of nutrients and glucose homeostasis. Hepatic gene expression is regulated largely at the transcriptional level. Liverenriched transcription factors bind cis-regulatory DNA elements to activate their target genes. The forkhead box proteins, Foxa1, Foxa2 and Foxa3, contain a highly conserved winged helix DNA-binding domain 1 and were initially discovered because of their ability to regulate the promoters of the genes encoding a1-antitrypsin and transthyretin 2 . The Foxa proteins, previously known as HNF-3a, HNF-3b and HNF-3g, are expressed in embryonic foregut endoderm, from which the liver forms at midgestation 3, 4 . Foxa1 and Foxa2 were shown by genetic means to be indispensable for the initiation of liver development 5 .
Tissue-specific transcriptional regulation is often combinatorial in nature, as promoters of target genes contain regulatory modules with multiple transcription factor binding sites 5 . Binding of Foxa factors to their targets is essential for several nuclear receptors to access their cis-regulatory elements. For example, the presence of Foxa2 binding sequences near glucocorticoid response elements in the liver is necessary for maximal induction of genes activated during the response to fasting 6 . In addition, Foxa binding sites are found adjacent to those for the androgen receptor in the regulatory regions of genes expressed in the epididymis and prostate 7 , and a nearby Foxa1 site is necessary for estrogen receptor-mediated gene activation in breast cancer cells 8, 9 . Thus, Foxa transcription factors are integral components of transcriptional regulatory networks in multiple organ systems.
Previous studies of Foxa2 overexpression in the liver have suggested that this transcription factor is key in lipid metabolism 10 . Because a gain-of-function approach involving overexpression of DNA-binding proteins can lead to activation or repression of nonphysiological targets, we used a loss-of-function mouse model to study the role of Foxa2 in the adult liver. Using cell type-specific gene ablation, we found that Foxa2 regulates multiple genes involved in hepatic bile acid homeostasis. We show further that Foxa2 is required to prevent hepatic cholestasis, liver injury and ER stress when mice are fed a diet containing cholic acid. Thus, we have identified a previously undescribed role for Foxa2 in hepatic bile acid homeostasis and in the prevention of cholestatic liver injury.
RESULTS

ChIP-on-chip analysis for Foxa2
Previous loss-of-function analysis has demonstrated an essential role for Foxa2 in the integration of gluconeogenic gene expression in response to fasting 6 . In addition, expression profiling of multiple paradigms of Foxa2 deficiency or Foxa2 misexpression has resulted in the identification of hundreds of genes whose messenger RNA levels can be influenced by changes in Foxa2 status [10] [11] [12] . However, expression profiling captures not only those genes that are directly dependent on Foxa2 binding to their cis-regulatory elements but also those controlled by intermediate regulators and even those controlled by compensatory changes in response to an altered physiological state. To identify the subset of genes directly regulated by Foxa2 in the liver, we performed genome-wide location analysis. Chromatin immunoprecipitation (ChIP) samples from livers of wild-type and Foxa2 liver-conditional null mice (Foxa2 loxP/loxP Alfp-Cre mice, which express Cre recombinase under the control of hepatocyte-specific mouse albumin regulatory elements and a-fetoprotein enhancers and which have two copies of a loxP site-flanked allele of the Foxa2 gene) 6 were hybridized to a mouse enhancer-promoter microarray with more than 36,000 elements. We identified 574 enhancer and promoter regions, corresponding to 484 unique genes, occupied by Foxa2 (Supplementary Table 1 online). We evaluated whether any functional categories were overrepresented in the Foxa2-bound targets as compared to all genes represented on the array (Supplementary Table 2 online). Strikingly, a cluster of categories of genes involved in lipid and steroid metabolism was identified as bound by Foxa2 by this assay system.
Foxa2-deficient livers accumulate bile acids
Given our findings from location analysis, we next considered whether cholesterol or bile acid homeostasis was disturbed in Foxa2-mutant mice. In the liver, a large proportion of cholesterol is eliminated by its conversion into bile acids and excretion into bile. Elevation of bile salts within hepatocytes leads to cholestatic liver disease. Although hepatic bile acid levels were elevated twofold (P o 0.05) in Foxa2 mutants (Fig. 1a) , serum bile acid concentrations were similar in Foxa2 loxP/loxP Alfp-Cre mice as compared to their wild-type littermates (Fig. 1b) . Because bile acid homeostasis was perturbed in Foxa2 mutants, we placed Foxa2 loxP/loxP Alfp-Cre mice and their control littermates on a diet containing cholic acid. Cholic acid supplementation has been used extensively to elucidate the transcriptional control of cholesterol and bile acid metabolism by members of the nuclear hormone receptor gene family, specifically farnesoid X receptor (Fxr, encoded by Nr1h4), pregnane X receptor (Pxr, encoded by Nr1i2) and short heterodimer partner receptor (Shp, encoded by Nr0b2) 13, 14 . Foxa2-mutant mice and their control littermates responded similarly to the cholic acid diet in terms of cholesterol and triglyceride metabolism (Fig. 1) . However, Foxa2-deficient mice showed markedly increased serum and hepatic bile acid content on the cholic acid diet (Fig. 1a,b) . Whereas serum and hepatic bile acid abundance increased threefold in control mice fed a cholic acid diet, they were elevated an additional twofold and threefold, respectively, in Foxa2-deficient mice (P o 0.02; Fig. 1a,b) .
Next, we investigated the consequences of the elevated hepatic bile acid levels in Foxa2-mutant mice on gene expression in the liver. Bile acids serve as ligands for Fxr, and, in a negative feedback loop, inhibit their own synthesis 15 . Fxr also activates the transcription of the gene encoding Shp, which inhibits expression of Cyp7a1, Cyp7b1, Cyp8b1 and Cyp27a1, crucial enzymes in bile acid synthesis, and of Ntcp (encoded by Slc10a1), a transporter mediating hepatic bile acid uptake from plasma in the last step of enterohepatic circulation. As reported previously 16 , Shp mRNA levels were increased approximately threefold in livers of mice fed a cholic acid diet (Fig. 1c) , an induction that is not dependent on the presence of Foxa2. Expression of Cyp7a1, the rate-limiting enzyme in bile acid synthesis, is no longer detectable after cholic acid treatment, and repression of other synthesis enzymes, such as Cyp7b1, Cyp8b1 and Cyp27a1, in livers of Foxa2-deficient mice is equivalent or more pronounced than in wild-type controls on cholic acid diet (Fig. 1c) . Thus, inappropriate expression of the enzymes responsible for hepatic bile acid synthesis is not the cause for cholestasis in Foxa2-mutant mice.
Strikingly, maximal activation of Shp transcription also occurs in Foxa2-deficient mice on standard chow (Fig. 1c) . Consequently, expression of the bile acid synthesis enzymes and Ntcp is also reduced in Foxa2 mutants fed a standard diet (Fig. 1c) . The induction of the Fxr target Shp is a probable secondary consequence of the elevated levels of bile acids within the Foxa2-deficient hepatocytes (Fig. 1a) . These molecular changes confirm our physiological findings of mild hepatic cholestasis in Foxa2-deficient mice even in the absence of cholic acid feeding. Elevated hepatic bile acid abundance under cholestatic conditions leads to liver damage 17 . Although, histologically, no hepatic injury was apparent in Foxa2-deficient mice fed standard chow (data not shown), Foxa2 loxP/loxP Alfp-Cre mice showed increased cholestatic injury compared to their control littermates on the cholic acid diet, as evidenced by hepatocyte dropout (Fig. 1d,e) . To further ascertain hepatic injury, we determined serum levels of the liver enzymes alanine aminotransferase and aspartate aminotransferase in mice on standard and cholic acid-supplemented diets. Whereas alanine aminotransferase or aspartate aminotransferase activity was not altered in Foxa2 loxP/loxP Alfp-Cre mice on standard chow, the liver enzyme levels were disproportionately increased in the mutant mice on the cholic acid diet, threefold and twofold, respectively, significantly differing from those of their littermate controls (Fig. 1f,g ). Together, these findings suggest that Foxa2 plays a part in protecting the liver from bile acid toxicity.
Foxa2 expression is reduced in human cholestatic livers
Because deletion of Foxa2 in hepatocytes leads to accumulation of bile acids in mice, we next considered whether expression of FOXA2 is changed under cholestatic conditions in humans (Fig. 2) . We examined hepatic FOXA2 protein abundance in two sets of subjects with cholestasis. FOXA2 protein was virtually undetectable in pediatric subjects with primary sclerosing cholangitis (PSC; Fig. 2a ) as well as in those with biliary atresia (Fig. 2b) . We also performed immunohistochemical staining with antibodies to FOXA2 of liver sections from two adult subjects with PSC, two pediatric subjects with biliary atresia and control pediatric and adult subjects. Whereas FOXA2 staining was clearly present in hepatocyte nuclei of controls (Fig. 2c,f) , FOXA2 expression was reduced in hepatocytes of subjects with PSC (Fig. 2d ,e) and biliary atresia (Fig. 2g,h ). Our results agree with previous reports showing a significant decrease in Foxa2 expression in rodent models of cholestasis 18 . Thus, cholestatic injury of differing etiologies causes downregulation of FOXA2 in humans, which together with our findings suggests that low FOXA2 levels exacerbate the injury to the liver.
Foxa2 regulates bile acid transporter genes
To determine the cause of bile acid accumulation in livers of Foxa2 loxP/loxP Alfp-Cre mice, we measured hepatic mRNA levels of bile acid transporters associated with cholestasis. Transporters located at the canalicular membrane include Bsep (encoded by Abcb11), a bile salt export pump, Mrp2 (encoded by Abcc2), a multispecific organic anion carrier involved in biliary secretion, and Mdr2 (encoded by Abcb4), which is essential for secreting phospholipids into bile. On the basolateral membrane, Mrp3 (encoded by Abcc3), Mrp4 (encoded by Abcc4), and Ost-a and Ost-b (encoded by Osta and Ostb) export bile acids and their conjugates from the hepatocyte back into circulation [19] [20] [21] , whereas Oatp1 (encoded by Slco1a1), Oatp2 (encoded by Slco1a4) and Oatp4 (encoded by Slco1b4) are involved in sodium-independent hepatic uptake of bile salts 22 . Expression of transporters in the Mrp family was altered in the absence of Foxa2. Both mRNA and protein levels of Mrp2 and Mrp4 were decreased in the livers of Foxa2-mutant mice on both standard chow and cholic acid-enriched feed (Fig. 3a,b) . Furthermore, the induction of Mrp3 normally seen in livers of mice fed a cholic acidsupplemented diet was blunted in the absence of Foxa2 (Fig. 3a,b) . Expression of Bsep did not change either on the mRNA or the protein level in Foxa2 loxP/loxP Alfp-Cre mice on either diet treatment (Fig. 3a,b) . Previous reports have also found no effect of cholic acid on Bsep expression in rodents 16 . However, mRNA levels of two isoforms of Mdr1, an alternative bile acid transporter 23 , were increased in Foxa2 mutants (significantly (P o 0.02) for Mdr1a in mice on a standard diet, with an increasing trend for Mdr1b in mice on a standard diet and Mdr1a in mice on a cholic acid diet) compared to their control littermates (Fig. 3a) .
In rodent models of Mrp2 deficiency, failure to export the endogenous substrates of Mrp2, which include bilirubin and other organic anions as well as conjugated bile acids, hinders efflux of biliary glutathione [24] [25] [26] . Glutathione is the principal osmotic force driving bile formation 27 . Thus, reduction in Mrp2 expression results in reduced bile flow 25, 26 and probably contributes to cholestasis in Foxa2-deficient livers. Administration of spironolactone, a synthetic 17-lactone drug used as an androgen antagonist, in a rat model of cholestasis, in which Mrp2 protein abundance is reduced but Bsep expression is not changed, leads to upregulation of Mrp2, normalization of bile flow, biliary excretion of glutathione and reduction of elevated serum bile acids to physiological levels 26 . In addition to reduced expression of Mrp2, Foxa2 loxP/loxP Alfp-Cre mice also show reduced expression of basolateral export proteins, including Mrp3 and Mrp4, when fed a cholic acid diet (Fig. 3a,b) . Expression of basolateral transporters in the Oatp family, which is involved in sodium-independent uptake of bile salts, is also affected in Foxa2-deficient hepatocytes. The mRNA levels of Oatp1 and Oatp2 are reduced by 50% and 90%, respectively, on standard diet, and the induction of Oatp2 normally seen in liver of mice fed a cholic acidsupplemented diet is blunted in the absence of Foxa2 (Fig. 3c) . Decreased levels of OATP2 are seen in individuals with inflammation-induced icteric cholestasis 28 and PSC 29 . Hence, reduced expression of Oatp2 probably contributes to elevated bile acids in the serum seen in Foxa2 loxP/loxP Alfp-Cre mice.
Mrp2, Mrp3 and Mrp4 are known to be controlled by Pxr and constitutive androstane receptor (Car, encoded by Nr1i3). In addition, the nuclear receptors Fxr (isoforms Fxra and Fxrb 30 ), Pxr and Car have been shown to play complementary parts in protecting the liver from bile acid toxicity 31 , and several other transcription factors (hepatic nuclear factor-1a (Hnf-1a), Hnf-1b and Hnf-4a) have been established to have a central role in bile acid metabolism [32] [33] [34] . Downregulation of Mrp2 and Mrp4 in Foxa2 loxP/loxP Alfp-Cre mice on standard chow could potentially be explained by a 50% decrease in Pxr expression (Fig. 3d) . However, the decreases in transporter gene expression in Foxa2 mutants on the cholic acid diet cannot be attributed to changes to the aforementioned hepatic transcription factors because none of them are dependent on Foxa2 under these conditions (Fig. 3d) .
Next, we wanted to ascertain whether the genes encoding bile acid transporters that were downregulated in Foxa2 mutants are direct targets of Foxa2. We performed ChIP with an antibody to Foxa2 on livers of wild-type and Foxa2 loxP/loxP Alfp-Cre mice. Quantitative PCR carried out on DNA immunoprecipitated from wild-type liver chromatin revealed that Foxa2 occupies binding sites located in the thirteenth intron of the gene encoding Mrp2 and about 2,150 base pairs upstream of the transcriptional start site of the gene encoding Oatp2 (Fig. 3) , suggesting that both Mrp2 and Oatp2 are direct targets of Foxa2 in vivo. This enrichment of the intron and promoter amplicons is eliminated in chromatin samples from Foxa2-deficient livers, confirming the specificity of the immunoprecipitation assay (Fig. 3e) .
Conversion of bile acids into their amino acid derivatives, which renders them more soluble, occurs in two steps. First, bile acid CoA ligase (encoded by Slc27a5) converts bile acids to their CoA thioesters. Then, bile acid-CoA amino acid N-acyltransferase (Baat) catalyzes the intermediates into bile acid CoA esters, which are excreted into bile 35 . Expression of Slc27a5 mRNA showed a downward trend in mice on a standard chow diet and was reduced by B50% (P o 0.05) in Foxa2 loxP/loxP Alfp-Cre mice on the cholic acid diet (Fig. 4a) . A ChIP assay confirmed that Foxa2 occupies a regulatory region in the second exon of Slc27a5 (Fig. 4b) , thus identifying bile acid CoA ligase as a direct transcriptional target of Foxa2. In contrast, mRNA levels of Baat did not change on either diet treatment (Fig. 4a) , suggesting that other transcription factors are more dominant in the regulation of this gene. The cumulative defects in expression of bile acid CoA ligase and the transporters discussed above explain the accumulation of bile acids in livers of Foxa2-deficient mice.
Deletion of Foxa2 in liver leads to ER stress An increase in bile acids in the liver is toxic and results in ER stress 36 . As bile acids are already elevated in livers of Foxa2 loxP/loxP Alfp-Cre mice on a regular diet, we examined whether hepatocytes from Foxa2 loxP/loxP Alfp-Cre mice showed signs of ER stress. We performed immunofluorescence staining of liver sections from Foxa2-deficient mice and their control littermates with antibodies to BiP, an ER chaperone that is upregulated during the unfolded protein response, and ubiquitin, a major component of the ubiquitin-proteasome system, which degrades misfolded proteins (Fig. 4c) . Mutant livers showed increased amounts of BiP and a dilated ER, consistent with ER stress 37 , as well as increased cytoplasmic ubiquitin (Fig. 4c) . Misfolded proteins migrate from the ER to the cytosol, where they are polyubiquitinated and degraded in the proteasome 38 . The merge of the two confocal images shows increased colocalization of BiP and ubiquitinated proteins in livers of Foxa2 loxP/loxP Alfp-Cre mice, suggesting an accretion of misfolded proteins in the ER caused by delay in their degradation, also a sign of ER stress 39 . Next, we examined expression of molecular markers of ER stress. These include regulators of the unfolded protein response, activating transcription factor-6, X-box-binding protein-1 (Xbp-1), Chop (also known as Gadd153, a transcription factor controlling ER stress-induced apoptosis, encoded by Ddit3) and BiP (encoded by Hspa5). For Xbp-1, we checked the expression of the original transcript and the spliced/ processed form (Xbp-1-p), the only form that activates the unfolded protein response efficiently. Quantitative PCR was performed on RNA isolated from livers of Foxa2 loxP/loxP Alfp-Cre mice and their control littermates on regular and cholic acid diets. Hepatic mRNA levels for ER stress transcription factors were elevated two-to ninefold, whereas expression of BiP increased approximately sixfold (Fig. 4d) in Foxa2 mutants. This indicates that the mild cholestasis due to absence of Foxa2 in the liver in mice fed standard chow is sufficient to induce ER stress in the mutant mice.
Foxa2 affects hepatic glutathione metabolism
Exposure of hepatocytes to hydrophobic bile acids during cholestasis has been linked to production of oxidative stress byproducts 40 . The tripeptide glutathione is the major antioxidant and redox regulator in vivo. In hepatocytes, glutathione detoxifies many reactive electrophilic molecules, which, when conjugated with glutathione, can be excreted into bile. The conjugation of these compounds is catalyzed by a family of glutathione S-transferase enzymes (GSTs), such as Gstm2, which was identified as a Foxa2 target by our location analysis (Supplementary Table 1 ). In addition, several genes classified as oxidoreductase enzymes were bound by Foxa2 in vivo (Supplementary Table 1 ). We measured mRNA levels of Gstm2 and two other GST enzymes, Gsta1 and Gsta2, in the livers of control and Foxa2-deficient mice and found that the genes encoding these enzymes were downregulated significantly on both standard chow and cholic acidsupplemented diets (Fig. 4e) . Whereas expression of Gsta1 and Gsta2 is activated somewhat in Foxa2 loxP/loxP Alfp-Cre mice by cholic acid feeding, the mRNA levels of these enzymes did not reach those observed in wild-type mice on either diet (Fig. 4e) . Expression of Gsta3, however, is not changed on either diet treatment (Fig. 4e) . mRNA levels of Gpx1, the enzyme converting oxidized glutathione to the reduced form, did not differ between Foxa2 mutants and their control littermates, as they increased similarly on the cholic acid diet (Fig. 4e) . Expression of Gclc, the rate-limiting enzyme of glutathione synthesis, was slightly downregulated in Foxa2 mutants on standard diet but upregulated twofold in Foxa2-knockout mice on the cholic acid diet, as total glutathione abundance was further decreased in these mice on bile acid treatment ( Supplementary Fig. 1 online) . We propose that the reduction in GST abundance in the knockout mice affects the conjugation of cholestatic byproducts to glutathione and their excretion into bile and contributes to the liver injury seen in Foxa2 loxP/loxP Alfp-Cre mice. Hepatic injury during cholestasis is ameliorated by hydroxylation and conjugation of bile acids with sulfate, rendering them more hydrophilic and less toxic 41 . Initially, Cyp3a11, a member of the cytochrome P450 family 3, converts bile acids into more hydrophilic compounds (in phase I detoxification) that are subsequently conjugated to sulfate (in phase II detoxification) by Sult2a1, a member of the sulfotransferase family 2A. Transcription of the genes that encode both enzymes is activated in response to cholestasis 42 . Whereas expression of both Cyp3a11 and Sult2a1 increased with cholic acid treatment of control mice, mRNA levels of Cyp3a11 were significantly downregulated in Foxa2 mutants fed either a standard or a cholic acid-enriched diet (Fig. 5a) . The lack of induction of Cyp3a11 during cholestasis is associated with liver injury 42, 43 . Therefore, reduced expression of this enzyme in Foxa2-mutant mice is probably contributing to the liver toxicity and increased liver damage observed in this model.
Cyp3a11 is a direct target of Foxa2, as shown by ChIP with primers specific for sites positioned about 180 and 80 base pairs upstream of the Cyp3a11 transcriptional start site (Fig. 5b) . This binding is absent in Foxa2-deficient liver, confirming the specificity of the assay (Fig. 5b) . These data extend previous findings that had identified a binding site for FOXA2 in the gene encoding the human ortholog of Cyp3a11, termed CYP3A4, in vitro 44 .
In summary, deletion of Foxa2 in hepatocytes causes a decrease in expression of bile acid transporters, on both the basolateral and the canalicular membranes, resulting in mild cholestasis (shown in a schematic in Fig. 6 ). Challenging Foxa2 mutants with a cholic acid diet leads to severe intrahepatic cholestasis and a disproportionate rise in serum bile acids. Accumulation of hepatic bile acids is exacerbated by reduced expression of GST and conjugation and hydroxylation enzymes and leads to ER stress and substantial liver injury in Foxa2 loxP/loxP Alfp-Cre mice.
DISCUSSION
The role of Foxa2 in hepatic transcriptional regulation has been studied previously using several paradigms of overexpression 10, 12 that produced conflicting results. Overexpression of a DNA-binding protein can lead to artificial effects, as binding sites with a weak consensus sequence, which are not normally targets, will be occupied by the exogenous protein present at supraphysiological levels. To overcome these limitations, we employed tissue-specific gene ablation to derive mice deficient in Foxa2 in hepatocytes. Our previous study of Foxa2 in the liver 45 focused on glucose metabolism because the majority of the Foxa targets known 10 years ago were genes involved in this process. In addition, we used a genome-wide enhancer-promoter microarray to identify the set of genes directly bound by Foxa2 in vivo, allowing us to identify numerous new Foxa2 targets in the liver. Using these combined approaches, we have shown that Foxa2 controls the expression of multiple genes involved in bile acid metabolism, which explains the cholestatic phenotype of Foxa2-mutant mice.
In a previous study, transgenic mice overexpressing rat Foxa2 in the liver showed elevated bile acids in serum, up to 50-fold by 6 weeks of age 12 . The phenotype was attributed to reduced expression of Ntcp, a sinusoidal transporter importing bile acids into the hepatocyte from Figure 6 A model for the regulation of hepatic bile acid homeostasis by Foxa2. Foxa2 regulates the expression of Mrp2 and Oatp2 directly and that of Mrp3 and Mrp4 indirectly. Mrp3 and Mrp4 facilitate export of bile acids from hepatocytes into circulation, and the organic anion carrier Oatp2 is involved in sodium-independent hepatic uptake of bile salts, whereas Mrp2 is involved in secretion of bile acids and their anionic conjugates into bile. Expression of conjugation enzymes Slc27a5, Gsta1, Gsta2 and Gstm2 also depends on Foxa2. Reduced conjugation of bile acids coupled with decreases in mRNA levels of the transporters owing to the absence of Foxa2 leads to elevated hepatic bile acid concentrations, which, in turn, cause ER stress. Expression of Cyp3a11 is directly controlled by Foxa2, as well. Cyp3a11 is crucial in hydroxylation of the hydrophobic bile acids, protecting the liver from bile acid toxicity. Together, ER stress and increased bile acid toxicity in Foxa2 loxP/loxP Alfp-Cre mice lead to liver injury.
circulation, a defect that preceded the 50-fold increase in serum bile acid levels. However, the endogenous expression of mouse Foxa2, as well as Foxa1, was completely abolished in this model, while that of Foxa3 and Onecut1 (commonly known as Hnf6) was reduced by about 70%. Hence, changes in gene expression in this transgenic model could be the consequence of altered levels of other transcription factors rather than of direct regulation by Foxa2. In addition, we observed a reduction in hepatic mRNA levels of Ntcp in Foxa2 loxP/loxP Alfp-Cre mice, opposite to what would have been predicted from the findings in the above-mentioned transgene model. Reduction in Ntcp expression is expected in our mouse model, as elevated bile acid levels activate Shp, which inhibits Ntcp transcription in a mechanism to reduce bile acid import, protecting the hepatocyte from bile acidmediated damage in cholestatic conditions 46 . Downregulation of Ntcp, as is seen in obstructive cholestasis, is occasionally associated with an increase in serum bile acid 47 , but this increase depends on the load from the intestine and the capacity of the basolateral bile acid transporters. The reduction in Ntcp expression we see in Foxa2-mutant mice fed a normal diet is not severe enough to be a limiting factor. However, when these mice are fed a cholic acid-containing diet, the bile salt load from the intestine increases substantially and serum bile salt levels become elevated. Furthermore, hepatocyte damage observed in the study with transgenic mice overexpressing rat Foxa2 was attributed to diminished expression of Mdr2, a canalicular phospholipid transporter 12 . Expression of Mdr2 is not changed in our loss-of-function model.
In another study, the researchers performed an expression profile comparing wild-type mice expressing constitutively active adenoviral Foxa2T156A with controls infected with adenoviral GFP 10 . Overexpression of Foxa2 by this technique also raised expression of Foxa1, Foxa3, Hnf-4a and peroxisome proliferator-activated receptor-g, other transcription factors central to hepatic metabolism. A small subset of targets in this previous study and ours overlap. Expression of several genes, including those encoding Cyp7b1 and Oatp2, is elevated in the overexpression model and reduced in our loss-of-function model, supporting previous findings that Foxa2 is a transcriptional activator 48 . Although the adenoviral study had implicated Foxa2 in lipid metabolism 10 , it did not connect Foxa2 to bile acid metabolism in particular, nor did it identify expression changes for the bile acid transporters Mrp2 and Mrp4, the bile acid CoA ligase Slc27a5 or the hydroxylation enzyme Cyp3a11, all downregulated in our loss-of-function model and essential to explaining the cholestatic phenotype of Foxa2 loxP/loxP Alfp-Cre mice. The differences between the two gene lists could be explained by changes in other DNA-binding proteins in the overexpression model or by the possibility of Foxa2 contacting low-affinity binding sites in the adenoviral overexpression system 10 .
Deletion of Foxa2 in the liver leads to cholestasis, which is exacerbated when the feed is supplemented with cholic acid. Expression of Bsep, the major bile salt export pump thought to be responsible for most bile salt excretion, is not changed in the knockout mice on either the mRNA or the protein level. Instead, accumulation of hepatic bile acids in these mice on both standard and cholic acid diets can be explained by lowered hepatic mRNA and protein levels of several transporters of bile acids and their conjugates, including Mrp2, Mrp4 and Oatp2 and Mrp3, whose induction, normally seen in livers of mice fed a cholic acid-supplemented feed, is blunted in the absence of Foxa2.
Although mutations in the gene encoding Bsep have been associated with progressive intrahepatic cholestasis type 2 in humans, the phenotype of Bsep-deficient mice is much less severe 49 . Bsep-null mice show substantial bile acid secretion and are protected from severe cholestatic injury by hydroxylation of bile acids and by the existence of an alternative export system for bile acids, Mdr1. Mdr1 abundance is increased in Bsep-mutant mice 50 , just as it is in Foxa2-knockout mice. In addition, genetic variation in the gene encoding BSEP has been excluded in the etiology of several cholestatic conditions in humans, including primary biliary cirrhosis and PSC 51 . Thus, in humans, other than for intrahepatic cholestasis type 2, it appears that BSEP has a very limited role in intrahepatic cholestasis, and in mice, given the results from the genetic knockout studies, it seems that Bsep does not have a crucial role in bile salt export in that organism.
We also document that expression of the bile acid conjugation enzyme Slc27a5 is directly dependent on Foxa2. Slc27a5-knockout mice, although showing a severe conjugation defect, do not develop cholestasis because they express normal or even elevated levels of bile acid and bile acid conjugate transporters 35 . Expression of Bsep and Ntcp is upregulated in Slc27a5-deficient mice 35 . In contrast, reduced expression of conjugation enzymes in the Foxa2-knockout mice is coupled with a transporter defect, resulting in hepatic cholestasis.
Treatment with bile acids has been shown to induce ER stress 36 , which has been implicated in the pathogenesis of cholestatic liver disease. Although cholic acid diet also induces ER stress in wild-type mice, liver injury is exacerbated in Foxa2-deficient livers owing to downregulation of Cyp3a11, a key hydroxylation enzyme that protects the liver from cholestatic injury. CYP3A4, the human homolog of Cyp3a11, is the most abundant cytochrome P450 enzyme expressed in the liver. To our knowledge, we provide the first in vivo evidence that Foxa2 prevents hepatic ER stress and protects the liver from bile acid toxicity by activating Cyp3a11 expression.
Although previous reports have shown reduced nuclear Foxa2 expression in rodent models of reduced biliary secretion and biliary obstruction 18, 25 , we show that expression of FOXA2 is reduced in cholestatic livers from humans of various ages and with different etiologies. To our knowledge, this is the first study that connects FOXA2 to human cholestatic liver disease, and, together with our findings in the mouse model, that suggests that strategies to maintain FOXA2 expression in individuals with cholestasis might be a new therapeutic goal.
METHODS
Mice. The derivation of the Foxa2 loxP/loxP Alfp-Cre mouse model has been described previously 6 . All of our mice have been backcrossed to the CD1 mouse strain. We genotyped mice by PCR of tail DNA. We used 2-3-month-old male mice in all studies. We performed the bile acid feeding study with an experimental diet consisting of a standard rodent diet (PMI Laboratory 5010 autoclavable rodent diet) supplemented with 0.5% cholic acid. We placed mice on the cholic acid-supplemented diet for 7 d. At the end of the study, we fasted the mice, killed them, collected the blood from the vena cava and processed it to serum. All experiments were approved by the University of Pennsylvania School of Medicine Institutional Animal Care and Use Committee.
Human liver samples. The human pediatric liver samples were obtained from the Children's Hospital of Philadelphia's Liver and Bile Specimen Repository. The repository samples were obtained with informed consent as part of a protocol approved by the Children's Hospital of Philadelphia Internal Review Board. The specimens were collected at the time of liver transplantation and immediately frozen in liquid nitrogen. We fixed adult sections of livers in 10% neutral buffered formalin and then embedded them in paraffin. We obtained 5-mm sections for immunohistochemical staining.
Immunofluorescence and immunohistochemistry. We performed indirect immunofluorescence and immunohistochemistry as previously described 6 . We counterstained slides subjected to immunohistochemistry with hematoxylin. We used the following antibodies: rabbit antibody to ubiquitin RNA reverse transcription and real-time PCR. We isolated liver RNA from Foxa2 loxP/loxP Alfp-Cre and control littermates and performed quantitative RT-PCR as previously described 6 .
Chromatin immunoprecipitation. We performed ChIP and the real-time PCR reactions that followed as previously described 6 . We used snap-frozen mouse liver (100 mg) from wild-type and Foxa2-mutant mice (n ¼ 3 mice per group) to prepare chromatin. We performed immunoprecipitation with rabbit antiserum to Foxa2 (ref. 52) or control preimmune rabbit IgG (Upstate).
Western blot analysis. For nuclear extracts, we homogenized snap-frozen human liver (100 mg) in 1 ml of resuspension solution (10 mM HEPES pH 7.9, 1 mM EDTA, 60 mM KCl, 0.5% NP-40, 1 mM dithiothreitol and 1 mM PMSF) containing protease inhibitors (Roche). We centrifuged the homogenate at 1,500g for 5 min at 4 1C. We resuspended the remaining pellet in 250 ml of lysis buffer (50 mM Tris pH 7.5, 150 mM NaCl, 1% NP-40 and 0.5% sodium deoxycholic acid) with protease inhibitors. We sonicated the solution for 8 min with Bioruptor (Diogenode) and centrifuged at 14,000g for 1 min. We performed western blotting as previously described 53 . We used rabbit antibody to Foxa2 (ref. 52; 1:5,000) and rabbit antibody to TATA box-binding protein (1:100, Santa Cruz, sc-273) as primary antibodies. We prepared membrane fractions for protein expression of transporters with the Compartmental Protein Extraction Kit (K3012010, Biochain Institute). The primary antibodies used were rabbit antibody to Abcb11 (1:100, Abgent, AP6110a), rabbit antibody to Mrp2 (1:100, Kamiya Biomedical Company, MC-267), goat antibody to Mrp3 (1:100, Santa Cruz, sc-5775), rat antibody to Mrp4 (1:100, Santa Cruz, sc-59615) and mouse antibody to Na + /K + ATPase (1:2000, Santa Cruz, sc-48345).
Mouse enhancer-promoter microarray analysis. We performed amplification and labeling of immunoprecipitated chromatin as previously described 53 . We hybridized labeled DNA samples to two arrays, the Mouse PromoterChip BCBC-5A and the Mouse PromoterChip BCBC-5B. We performed statistical analyses of the microarray data with the significance of microarrays 54 package with a false discovery rate of 10% and fold change cutoff of 1.4.
Serum and tissue chemistry. Serum chemistry was analyzed by AniLytics. For tissue chemistry, we homogenized snap-frozen mouse liver (100 mg) in 0.5 ml of ice-cold PBS containing protease inhibitors (Complete, Roche) using a Kontes glass homogenizer (2 ml). We rinsed the homogenizer with an additional 0.5 ml of PBS solution and centrifuged the resulting 1-ml mixture at 600g at 4 1C for 10 min. We diluted the supernatant 5Â with PBS and centrifuged further at 105,000g at 4 1C for 90 min. We quantified the total bile acid content of the resulting supernatant, containing the cytosolic fraction, with the Bile Acid L3K Assay kit (Diagnostic Chemicals). We measured the protein concentration by Bradford assay. We determined hepatic cholesterol, nonesterified fatty acids and triglycerides with enzymatic assay kits (all from Wako).
Sequence analysis. We used the Matrix Search sequence analysis tool (http://rulai.cshl.edu/cgi-bin/TRED/tred.cgi?process¼analysisMatrixForm) to scan regulatory regions of prospective Foxa2 targets from the enhancerpromoter microarrays for Foxa2 binding sites. We used the MSCAN algorithm (http://www.cisreg.ca/cgi-bin/mscan/MSCAN/) to detect potential clusters of Foxa2 binding sites in genomic sequences. Conservation of Foxa2 binding sites was determined with CONREAL software (http://conreal.niob.knaw.nl/) and visualized with the Vertebrate Multiz Alignment and Conservation track of the UCSC Genome Browser (http://genome.ucsc.edu/).
Statistical analyses.
We compared quantitative PCR data and metabolic measurements by unpaired Student's t-test. A P value below 0.05 was considered significant for all analyses. All values are represented as means ± s.e.m.
Additional methods. Detailed methodology is described in Supplementary Methods online.
Accession codes. Mouse enhancer-promoter microarray data have been deposited into ArrayExpress with accession code E-MEXP-1675.
Note: Supplementary information is available on the Nature Medicine website.
